CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists

Journal of Immunological Methods

Volumn 414, Issue , 2014, Pages 82-90

  Dammermann, Werner ^a   Bochmann, David ^a   Bentzien, Frank ^a   Komorowski, Lars ^b   Steinhagen, Katja ^b   Ullrich, Sebastian ^a   van Lunzen, Jan ^a   Lüth, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute of Experimental Immunology   (Germany)

Author keywords

Agonist; CMV; Cytomegalovirus; Interferon gamma release assay; Toll like receptor

Indexed keywords

BROPIRIMINE; CYTOMEGALOVIRUS ANTIGEN PP65; FLAGELLIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; LOXORIBINE; PEPTIDOGLYCAN; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT ANTIGEN; RESIQUIMOD; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR AGONIST; ZYMOSAN; BIOLOGICAL MARKER; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; IL2 PROTEIN, HUMAN; MATRIX PROTEIN; PHOSPHOPROTEIN; TOLL LIKE RECEPTOR; VIRUS ANTIGEN;

ADULT; ARTICLE; BLOOD; CELL LYSATE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INTERFERON GAMMA RELEASE ASSAY; MALE; MIDDLE AGED; NONHUMAN; NORMAL HUMAN; PROTEIN EXPRESSION; SECRETION (PROCESS); SENSITIVITY AND SPECIFICITY; SEROLOGY; VIRION; AGONISTS; CYTOMEGALOVIRUS INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; SYNTHESIS; VIROLOGY;

CYTOMEGALOVIRUS;

ADULT; ANTIGENS, VIRAL; BIOLOGICAL MARKERS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; INTERLEUKIN-2; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLY I-C; TOLL-LIKE RECEPTORS; VIRAL MATRIX PROTEINS;

EID: 84914163585     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.10.011     Document Type: Article

References (24)

1. Abate D., Saldan A., Mengoli C., Fiscon M., Silvestre C., Fallico L., Peracchi M., Furian L., Cusinato R., Bonfante L., Rossi B., Marchini F., Sgarabotto D., Rigotti P., Palu G. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantifer on gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J. Clin. Microbiol. 2013, 51:2501.
2. Abate D., Saldan A., Forner G., Tinto D., Bianchin A., Palu G. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants. J. Virol. Methods 2013, 196:157-162.
3. Abu-Khader A., Krause S. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation-a comparison of different assays for the detection of cytomegalovirus-specific T cells. Eur. J. Haematol. 2013, 91:534.
4. Aguero-Rosenfeld M.E., Wang G., Schwartz I., Wormser G.P. Diagnosis of lyme borreliosis. Clin. Microbiol. Rev. 2005, 18:484.
5. Burdash N., Fernandes J. Lyme borreliosis: detecting the great imitator. J. Am. Osteopath. Assoc. 1991, 91:573.
6. Chakera A., Bennett S.C., Cornall R.J. A whole blood monokine-based reporter assay provides a sensitive and robust measurement of the antigen-specific T cell response. J. Transl. Med. 2011, 9:143.
7. Clari M.A., Munoz-Cobo B., Solano C., Benet I., Costa E., Remigia M.J., Bravo D., Amat P., Navarro D. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin. Vaccine Immunol. 2012, 19:791.
8. Dammermann W., Wollenberg L., Bentzien F., Lohse A., Luth S. Toll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFNgamma release in whole blood during recall antigen responses. J. Immunol. Methods 2013, 396:107.
9. Fleming T., Dunne J., Crowley B. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J. Med. Virol. 2010, 82:433.
10. Gaur R.L., Suhosk M.M., Banaei N. In vitro immunomodulation of a whole blood IFN-gamma release assay enhances T cell responses in subjects with latent tuberculosis infection. PLoS One 2012, 7:e48027.
11. Glatz M., Fingerle V., Wilske B., Ambros-Rudolph C., Kerl H., Mullegger R.R. Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans. Dermatology 2008, 216:93.
12. Goossens H.A., Nohlmans M.K., van den Bogaard A.E. Epstein-Barr virus and cytomegalovirus infections cause false-positive results in IgM two-test protocol for early Lyme borreliosis. Infection 1999, 27:231.
13. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Danziger-Isakov L., Humar A. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013, 96:333.
14. Lalvani A., Pareek M. Interferon gamma release assays: principles and practice. Enferm. Infecc. Microbiol. Clin. 2010, 28(4):245-252.
15. Lisboa L.F., Kumar D., Wilson L.E., Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012, 93:195.
16. Sitaru C., Dahnrich C., Probst C., Komorowski L., Blocker I., Schmidt E., Schlumberger W., Rose C., Stocker W., Zillikens D. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp. Dermatol. 2007, 16:770.
17. Steere A.C., McHugh G., Damle N., Sikand V.K. Prospective study of serologic tests for lyme disease. Clin. Infect. Dis. 2008, 47:188.
18. Streeton J.A., Desem N., Jones S.L. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int. J. Tuber. Lung Dis. 1998, 2:443.
19. Tey S.K., Kennedy G.A., Cromer D., Davenport M.P., Walker S., Jones L.I., Crough T., Durrant S.T., Morton J.A., Butler J.P., Misra A.K., Hill G.R., Khanna R. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 2013, 8:e74744.
20. Thoden J., Potthoff A., Bogner J.R., Brockmeyer N.H., Esser S., Grabmeier-Pfistershammer K., Haas B., Hahn K., Harter G., Hartmann M., Herzmann C., Hutterer J., Jordan A.R., Lange C., Mauss S., Meyer-Olson D., Mosthaf F., Oette M., Reuter S., Rieger A., Rosenkranz T., Ruhnke M., Schaaf B., Schwarze S., Stellbrink H.J., Stocker H., Stoehr A., Stoll M., Trader C., Vogel M., Wagner D., Wyen C., Hoffmann C. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/OAG) (AWMF 055/066). Infection 2013, 41(Suppl. 2):S91.
21. Torres-Madriz G., Boucher H.W. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis. 2008, 47:702.
22. Walker S., Fazou C., Crough T., Holdsworth R., Kiely P., Veale M., Bell S., Gailbraith A., McNeil K., Jones S., Khanna R. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 2007, 9:165.
23. Weseslindtner L., Kerschner H., Steinacher D., Kundi M., Jaksch P., Simon B., Hatos-Agyi L., Scheed A., Klepetko W., Puchhammer-Stockl E. Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients. Clin. Exp. Immunol. 2013, 173:438.
24. Westall G.P., Mifsud N.A., Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am. J. Transplant. 2008, 8:1749.